Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial.

about

Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial.

Item

http://www.wikidata.org/entity/Q41523077

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Glycoprotein YKL-40: A potenti ...... sed controlled NEO-RACo trial.

@en

type

Item

label

Glycoprotein YKL-40: A potenti ...... sed controlled NEO-RACo trial.

@en

prefLabel

Glycoprotein YKL-40: A potenti ...... sed controlled NEO-RACo trial.

@en

P1476

Glycoprotein YKL-40: A potenti ...... ised controlled NEO-RACo trial

@en

P2093

Eeva Moilanen

http://www.w3.org/2001/XMLSchema#string

Hannu Kautiainen

http://www.w3.org/2001/XMLSchema#string

Kari Laiho

http://www.w3.org/2001/XMLSchema#string

Marjatta Leirisalo-Repo

http://www.w3.org/2001/XMLSchema#string

Markku J Kauppi

http://www.w3.org/2001/XMLSchema#string

Markku Korpela

http://www.w3.org/2001/XMLSchema#string

NEO-RACo Study Group

http://www.w3.org/2001/XMLSchema#string

Oili Kaipiainen-Seppänen

http://www.w3.org/2001/XMLSchema#string

Pekka Hannonen

http://www.w3.org/2001/XMLSchema#string

Riina Nieminen

http://www.w3.org/2001/XMLSchema#string

P2860

IL-6, but not TNF-α, increases plasma YKL-40 in human subjects

Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity

Localization of MHC class II/human cartilage glycoprotein-39 complexes in synovia of rheumatoid arthritis patients using complex-specific monoclonal antibodies

Induction and expression of human cartilage glycoprotein 39 in rheumatoid inflammatory and peripheral blood monocyte-derived macrophages

Changes in plasma IL-6, plasma VEGF and serum YKL-40 during Treatment with Etanercept and Methotrexate or Etanercept alone in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy

YKL-40 as a novel factor associated with inflammation and catabolic mechanisms in osteoarthritic joints

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

P304

e0183294

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0183294

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Katriina Vuolteenaho

Timo Möttönen

P577

2017-08-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28841649

http://www.w3.org/2001/XMLSchema#string

P921

biomarker

P932

5571914

http://www.w3.org/2001/XMLSchema#string